
|
Stock Quote (NASDAQ: DNDN)
Price:
8.62
Change:
- 0.22
Volume:
4,115,000
4:03 PM ET on May 16, 2012
Delayed at least 20 minutes.
Provided by eSignal. |
Dendreon Corporation is a biotechnology company focused on targeting cancer and transforming lives through the discovery, development and commercialization of novel therapeutics that may significantly improve cancer treatment options for patients.
May 16, 2012
Dendreon Announces Presentation of PROVENGE Data at the 2012 American Society of Clinical Oncology Annual Meeting
May 7, 2012
Dendreon Reports Net PROVENGE Product Revenues of $82 Million, Achieved 6.5% Quarter-Over-Quarter Growth
May 16, 2012 at 5:00 PM PT
Bank of America Merrill Lynch 2012 Health Care Conference in Las Vegas
May 9, 2012 at 11:15 AM CT
Baird's 2012 Growth Stock Conference
| MEDCAC 11.17.10 Presentation |
|
397.5 KB |
| Updated Results of the IMPACT Trial of Sipuleucel-T for Metastatic, Castration-Resistant Prostate Cancer (CRPC) |
|
421.1 KB |
Investor Relations |
Media |